Roche and Blueprint agree to end collaboration for cancer drug Gavreto

Roche is returning development and commercialization rights for cancer drug Gavreto to Blueprint Medicines.

The two companies are dissolving their collaboration following a Roche decision to opt out for “strategic reasons,” a Blueprint spokesperson told Endpoints News in an email. The return of the rights to Blueprint excludes Gavreto in Greater China where Roche already has a license agreement with CStone Pharmaceuticals to commercialize the drug, according to a news release on Thursday.